« Return to News | Clinical Intelligence

Halozyme initiates randomized phase II trial of PEGPH20 in pancreatic cancer

Thursday, April 25, 2013 08:00 AM

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, initiated a phase II multicenter, randomized clinical trial evaluating PEGPH20, a proprietary, investigational drug as a first-line therapy for patients with stage IV metastatic pancreatic cancer.

Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. The primary outcome will be to measure progression-free survival between patients administered PEGPH20 to those who are not.

"Pancreatic cancer is an extremely difficult disease to treat, in part because of a hyaluronan-rich matrix which shields these tumors against chemotherapy," said Daniel D. Von Hoff, M.D., F.A.C.P., lead principal investigator of the study and CSO for Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and physician-in-chief for the Translational Genomics Research Institute (TGen). "Ongoing translational studies indicate that PEGPH20 may deplete this matrix component from pancreatic tumors and alter the tumor environment in a way that renders these cancers more vulnerable to therapy."

Gregory I. Frost, Ph.D., president and CEO of Halozyme, added, "We are hopeful that these studies with PEGPH20 will improve patient outcomes for this insidious disease while advancing our general understanding of the unique tumor environment.”

Halozyme recently completed enrollment of a single-arm phase Ib trial in a similar patient population treated with PEGPH20 and gemcitabine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.